Stockscreener 앱 받기
2.40
0.00%
0.00
시간 외 거래:
2.34
-0.06
-2.50%
Gri Bio Inc 주식(GRI)의 최신 뉴스
Short Covering: What makes GRI Bio Inc stock attractive todayWeekly Earnings Recap & High Win Rate Trade Tips - baoquankhu1.vn
GRI PE Ratio & Valuation, Is GRI Overvalued - Intellectia AI
Aug Drivers: Is GRI Bio Inc a top pick in the sector2025 Price Action Summary & Free High Return Stock Watch Alerts - baoquankhu1.vn
GRI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Loss Report: Is GRI Bio Inc stock a smart retirement pickWeekly Gains Report & AI Based Buy and Sell Signals - baoquankhu1.vn
Geopolitics Watch: Can GRI Bio Inc reach all time highs this yearPortfolio Growth Summary & AI Forecast Swing Trade Picks - baoquankhu1.vn
Growth Review: Is GRI Bio Inc stock a smart retirement pick2025 Analyst Calls & Weekly Top Performers Watchlists - baoquankhu1.vn
Is GRI Bio Inc. a momentum stockJuly 2025 Movers & Technical Buy Zone Confirmations - mfd.ru
Market Leaders: What dividend growth rate does CHGG offerJuly 2025 Action & Verified Short-Term Plans - baoquankhu1.vn
Investor Mood: Is GRI Bio Inc stock a smart retirement pickQuarterly Risk Review & Real-Time Volume Surge Alerts - baoquankhu1.vn
GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment - The Globe and Mail
GRI Bio CEO, Marc Hertz, Featured in Virtual Investor 'What This Means” Segment - The Manila Times
GRI Bio, Inc. Discusses Positive Phase 2a Data in Idiopathic Pulmonary Fibrosis During Virtual Investor Segment - Quiver Quantitative
New IPF trial data: GRI Bio CEO explains lung repair signals - Stock Titan
Can GRI Bio Inc. stock maintain growth trajectoryProduct Launch & AI Powered Market Entry Strategies - mfd.ru
[SCHEDULE 13G/A] GRI Bio, Inc. Amended Passive Investment Disclosure - Stock Titan
GRI Stock Down on Public Offering Despite Encouraging IPF Study Data - MSN
Is GRI Bio Inc. showing insider buyingJuly 2025 PreEarnings & Daily Technical Stock Forecast Reports - mfd.ru
GRI Bio: Positive phase 2A IPF results and IND plans for lupus program signal strong pipeline momentum - TradingView
GRI Bio: Positive phase 2A IPF data and pipeline progress position GRI Bio for key upcoming milestones - TradingView
Can GRI Bio Inc. reach all time highs this yearStock Surge & Free Growth Oriented Trading Recommendations - mfd.ru
Levels Update: Is now the right time to enter SHF Holdings IncPortfolio Value Report & Verified Momentum Stock Watchlist - baoquankhu1.vn
GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - Yahoo Finance
GRI Bio reports $8.2 million cash position, extends runway into Q1 2027 - Investing.com Canada
GRI Bio sees cash runway into 1Q27 - TipRanks
GRI Bio raises $14.5 mln to fund operations into Q1 2027 - TradingView
GRI Bio: Strong cash position and positive clinical data support continued pipeline advancement - TradingView
GRI Bio, Inc. Reports Strong Cash Position and Positive Phase 2a Results for GRI-0621 in Pulmonary Fibrosis - Quiver Quantitative
GRI Bio Reiterates Full Year 2025 Financial Results, - GlobeNewswire
GRI Bio (GRI) Price Target Increased by 2,700.00% to 656.88 - Nasdaq
Dip Buying: Is CALX forming bullish engulfing patternsForecast Cut & Free Reliable Trade Execution Plans - baoquankhu1.vn
Aug Summary: What makes GRI Bio Inc stock attractive todayJuly 2025 Rallies & Low Drawdown Trading Techniques - baoquankhu1.vn
Trading Recap: Can OACCU deliver consistent dividendsJuly 2025 Final Week & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Gri Bio Warns of Ongoing Internal Control Weaknesses That Could Threaten Financial Reporting Reliability and Investor Confidence - TipRanks
Rate Cut: Is GRI Bio Inc forming a double bottomQuarterly Portfolio Report & AI Based Trade Execution Alerts - baoquankhu1.vn
Buyback Watch: Is JVSPAC Acquisition Corp Equity Right a momentum stockEarnings Overview Summary & Low Risk Entry Point Tips - baoquankhu1.vn
GRI Bio: 2025 net loss rose to $12M as R&D spending increased; more capital needed for future trials - TradingView
GRI Bio, Inc. SEC 10-K Report - TradingView
GRI Bio Expands At-The-Market Equity Offering Capacity - TipRanks
GRI Bio May Offer Up To $250 Million In SecuritiesSEC Filing - TradingView
Movement Recap: Can GRI Bio Inc be recession proof2025 Bull vs Bear & Weekly High Return Forecasts - baoquankhu1.vn
GRI Bio Reports Positive Study Results For Chronic Lung Disease, But Stock Slumps 20% — What Happened? - Asianet Newsable
GRI Bio reports positive gene expression data for IPF drug candidate - Investing.com Nigeria
What’s the RSI of GRI Bio Inc. stockQuarterly Portfolio Review & AI Forecasted Stock Moves - mfd.ru
GRI Bio delivers additional data from Phase 2a study of GRI-0621 - TipRanks
GRI Bio Reports New Phase 2a Gene Expression Data Supporting Anti-Fibrotic Activity Of GRI-0621 - Nasdaq
GRI Bio reports promising Phase 2a data in IPF - TipRanks
GRI Bio stock soars after gene data shows IPF drug targets disease drivers - Investing.com Nigeria
GRI Bio stock soars after gene data shows IPF drug targets disease drivers By Investing.com - Investing.com South Africa
GRI Bio, Inc. Announces Positive Phase 2a Clinical Trial Data for GRI-0621 - TradingView
GRI Bio, Inc. Reports Positive Phase 2a Results for GRI-0621 as Disease-Modifying Therapy in Idiopathic Pulmonary Fibrosis - Quiver Quantitative
Early lung fibrosis trial hints drug may help repair damaged lung tissue - stocktitan.net
Market Leaders: Can Docebo Inc weather a recessionWeekly Trade Summary & Consistent Income Trade Recommendations - baoquankhu1.vn
3.69%
0.68%
자본화:
|
볼륨(24시간):